60 results about "Mannose binding" patented technology

The present invention relates to pharmaceutical compositions comprising MBL and / or MBL variants. In particular the invention relates to pharmaceutical compositions comprising at least 200 μg / ml protein containing material, wherein mannan binding lectin (MBL) and / or MBL variants constitutes at least 35% (w / w) of the total protein; or to compositions comprising at least 400 μg / ml mannan binding lectin (MBL) and / or MBL variants. In addition the invention relates to pharmaceutical compositions comprising MBL and / or MBL variants and divalent cations. The invention also describes methods of preparing said compositions.The pharmaceutical compositions according to the invention may for example be used in methods of treatment of a number of different clinical conditions including infections. Uses of the compositions for preparation of medicaments for treatment of a clinical condition are also described.

Fusion proteins having sequences that target specific moieties such as carbohydrates, lipids, and / or proteins that are associated with certain cell types and / or pathogens; and a sequence that induces effector function are provided. The disclosure also provides nucleic acids encoding the fusion proteins, as well as pharmaceutical compositions, methods of use, and methods of treating conditions or diseases such as infectious diseases, cancers, immune related disorders and other ailments, that include the fusions proteins described herein.

Disclosed is Polygonatum cyrtonema Hua.Lectin II (PCL II), a plant protein isolated and purified from Siberian solomonseal rhizome, which has very strong inhibitory action to human immunodeficiency virus (HIV), thus can be used for preparing medicament for the prevention and treatment of AIDS.

The invention relates to contrast agents for medical science, in particular to a lymph targeted nuclear magnetic resonance imaging contrast agent with brown algal polysaccharide serving as a carrier and a preparation method and application of the lymph targeted nuclear magnetic resonance imaging contrast agent with the brown algal polysaccharide serving as the carrier. The macromolecular contrast agent high in water solubility is prepared by taking the brown algal polysaccharide as the carrier, taking mannose or mannose derivatives as a mannose receptor MBP (mannose binding protein) recognition group and taking paramagnetic metal ion chelates as a nuclear magnetic resonance imaging group. Lymph tissue binding force is increased, and combination of the mannose or mannose derivative group introduced into the synthetic contrast agent with mannose receptors enriched in lymph tissues is realized. In addition, after hypodermic injection of the contrast agent, lymph vessels and lymph glands are clearly developed under scanning of a nuclear magnetic resonance equipment, lymph gland signal enhancement rate of one side, with the contrast agent injected, of an animal body is remarkably increased while enhancement time is remarkably prolonged, distinct drawing and precise positioning of the lymph glands and the lymph vessels are realized, and a great significance to examination and diagnosis of lymphatic diseases is achieved.

Maintenance of quiescent hematopoietic stem and progenitor cells (HSPC) in culture without the addition of exogenous growth factors is an important aspect in clinical hematology. A recent report described the ability of Flt3 receptor-interacting lectin (FRIL) in the maintenance of cord blood (CB) derived progenitors in vitro. Since FRIL is a mannose binding lectin, the effectiveness of four such lectins of well-characterized specificities on the preservation of HSPC of CB origin have been examined. The HSPC preservation activity of lectins was assessed by in vitro colony forming unit (CFU) and long-term culture initiating cell (LTC-IC) assays. It was found that all four lectins had a HSPC preservation activity at least up to 30 days in culture without addition of exogenous growth factors. The results indicate that use of such lectins may provide a cost effective method of HSPC maintenance for clinical use.

The present invention provides engineered molecular opsonins that can be used to bind biological pathogens or identify subclasses or specific pathogen species for use in patients suffering from infectious diseases, blood-borne infections or sepsis In devices and systems for treatment and diagnosis. One aspect of the present invention provides mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on nearly all kinds of biological pathogens (viruses, bacteria, fungi, protozoa) makes engineered forms of MBL extremely useful in the diagnosis and treatment of infectious diseases and sepsis.